March 26, 2018 08:59 AM EDT

FDA hands a ‘breakthrough’ designation to Seattle Genetics’ pivotal-stage cancer drug enfortumab

John Carroll

Editor & Founder

Seattle Genetics and their partners at Astellas got a boost from the FDA today for their quest to score an accelerated approval for enfortumab vedotin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA hands a ‘breakthrough’ designation to Seattle Genetics’ pivotal-stage cancer drug enfortumab

John Carroll

Editor & Founder

Sign up to read this article for free.

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA hands a ‘break­through’ des­ig­na­tion to Seat­tle Ge­net­ics’ piv­otal-stage can­cer drug en­for­tum­ab

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA hands a ‘breakthrough’ designation to Seattle Genetics’ pivotal-stage cancer drug enfortumab

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus